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Objectives This study aimed to evaluate the performance of cardiac magnetic resonance (CMR), cardiac biomarkers, and
endomyocardial biopsy (EMB) results to predict left ventricular reverse remodeling (LVRR) in individuals with
recent-onset dilated cardiomyopathy (DCM).
Background LVRR is a marker of a favorable prognosis in individuals with recent-onset DCM. We used the aforementioned
novel methods of prognostication to predict this event.
Methods A total of 44 consecutive patients with recent-onset DCM underwent at baseline CMR, measurement of biomark-
ers and EMB together with conventional methods, including cardiopulmonary exercise testing and echocardiogra-
phy. Measurement of B-type natriuretic peptide (BNP) and the cardiological examination were repeated at 3, 6,
and 12 months. CMR was repeated at 12 months. LVRR was defined as an absolute increase in left ventricular
ejection fraction from 10% to a final value of 35% accompanied by a decrease in left ventricular end-
diastolic dimension 10% at 12 months of follow-up.
Results LVRR was observed in 20 individuals (45%) at 12 months. At baseline, a lower extent of late gadolinium en-
hancement (odds ratio [OR]: 0.67 [95% confidence interval (CI): 0.50 to 0.90]; p  0.008) and a higher myocar-
dial edema ratio (OR: 1.45 [95% CI: 1.04 to 2.02]; p  0.027) measured by CMR were independent predictors
of LVRR. At 3 months, the latest BNP plasma level (OR: 0.14 [95% CI: 0.02 to 0.94] per log BNP; p  0.047)
was the strongest predictor of LVRR.
Conclusions Both CMR and serial BNP testing provide a better prediction of LVRR in recent-onset DCM than EMB results,
other biomarkers, and the conventional methods of follow-up. (J Am Coll Cardiol 2013;61:54–63) © 2013 by
the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.072p
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pDilated cardiomyopathy (DCM) is a heterogeneous cardiac
disease of variable etiology. Genetic factors and inflamma-
tory or toxic effects have been shown to play a significant
role, and etiology often remains undetermined (1). The
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accepted July 3, 2012.rognosis of patients with DCM has improved over the past
decades as a result of advances in pharmacotherapy of
eart failure (2). Patients with recent onset of DCM have a
igher potential for so-called reverse remodeling (LVRR),
efined as improvement in left ventricular ejection fraction
LVEF) accompanied by a decrease in left ventricular
olume and end-diastolic dimension (LVEDD). In this
opulation, LVRR may be attributed either to resolved
See page 64
activity of underlying disease or to beneficial effects of phar-
macotherapy. Despite the proven strong association between
LVRR and favorable prognosis (3), far less is known about the
pathophysiology of LVRR and prediction of LVRR in clinical
practice. In this respect, contrast-enhanced cardiac magnetic
resonance (CMR) that visualizes the extent of myocardial
damage and myocardial edema in individuals with myocarditis
could provide new insights into the process of LVRR (4). In
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January 8, 2013:54–63 Left Ventricular Reverse Remodeling in DCMaddition, novel biomarkers, such as high-sensitivity cardiac
troponin T (hs-cTNT), B-type natriuretic peptide (BNP), and
galectin-3, could elucidate mechanisms of LVRR and/or
predict this event because they are closely associated with
myocyte necrosis, myocardial wall stress, and remodeling, as
well as with the prognosis. Finally, viral persistence (5) and
mmunohistochemical signs of inflammation (6) in myocardial
biopsies were associated with worsening of LVEF in individ-
uals suspected to have myocarditis.
Prediction of LVRR could have important clinical impli-
cations, especially for the cost-effective use of implantable
cardioverter-defibrillators and optimal timing of transplan-
tation referral in DCM patients. Therefore, we decided to
study the performance of CMR, biomarkers, and endomyo-
cardial biopsy (EMB), in comparison with conventional
methods, to predict LVRR in individuals with recent-onset
DCM.
Methods
Study population. Consecutive DCM patients with a his-
tory of symptoms shorter than 6 months were enrolled in
this prospective study. They were admitted to a tertiary
hospital between November 2008 and November 2010.
DCM was defined by the presence of left ventricular
dilation (LVEDD 33 mm/m in men and 32 mm/m in
omen) and LVEF 45% in the absence of coronary artery
isease, severe systemic arterial hypertension and primary
alve disease (1,7). Individuals with a history of drug abuse
r excessive alcohol consumption and/or presenting with
ersistent supraventricular tachyarrhythmias were not in-
luded. The investigation was approved by the local ethics
ommittee. All subjects gave their written informed consent
rior to their participation in the study.
tudy protocol. At baseline, all subjects underwent a
linical assessment, electrocardiography, echocardiography,
ardiopulmonary exercise testing, CMR, and EMB. Periph-
ral venous blood was obtained in the morning before EMB
or the measurement of hs-cTNT, BNP, and galectin-3 and
or routine biochemical analysis. Pharmacotherapy of heart
ailure was optimized according to the latest guidelines (8).
linical evaluation, electrocardiography, echocardiography,
ardiopulmonary exercise testing, routine biochemical anal-
sis, and measurement of BNP were repeated at 3, 6, and 12
onths of follow-up. The study was completed by CMR at
2 months of follow-up. Individuals admitted with decom-
ensated heart failure were treated to be euvolemic before
ny study visit.
LVRR was defined as an absolute increase in LVEF from
10% to a final value of 35%, accompanied by a decrease
n LVEDD 10% as assessed by echocardiography at 12
onths. Doses of angiotensin-converting enzyme inhibi-
ors, angiotensin receptor blockers, and beta-blockers were
xpressed as a percentage of the maximum recommended
aily dose according to the latest European Society of
ardiology guidelines (8). mchocardiography and cardio-
ulmonary exercise testing. Echo-
ardiography was performed by ex-
erienced operators in accordance
ith guidelines of the American So-
iety of Echocardiography (7,9).
-mode, 2-dimensional images,
nd Doppler recordings were ob-
ained using a Vivid 7 (GE Health-
are, Chalfont St Giles, United
ingdom). LVEF was assessed
sing Simpson’s biplane method.
itral regurgitation was graded
emiquantitatively on a scale of
one, trivial, mild, moderate, and
evere. Mitral inflow pattern was
lassified as restrictive in the pres-
nce of an E-wave deceleration
ime 120 ms or a ratio of early
ransmitral flow velocity to atrial
ow velocity 2 associated with
n E-wave deceleration time
150 ms (10). Cardiopulmonary
xercise testing was performed us-
ng a symptom-limited bicycle er-
ometry and 25-W increases in
orkload every 3 min. Minute
entilation, oxygen consumption,
nd carbon dioxide output were
easured by a heated pneumota-
hograph and mass spectrometry (Sensormedics system, Viasys
ealthcare, Conshohocken, Pennsylvania), as reported previ-
usly (11).
ardiovascular magnetic resonance. The CMR studies
ere performed on a clinical 1.5-T MR scanner (Avanto,
iemens Medical Solutions, Erlangen, Germany).
lectrocardiogram-gated steady-state free precision imag-
ng of the left and right ventricles was undertaken (repeti-
ion time [TR]/echo time [TE] 65/1.2 ms; flip angle 70°)
ith a slice thickness of 8 mm in contiguous short-axis and
rthogonal long-axis planes. A breath-hold, T2-weighted
ark blood sequence (TR/TE  2 RR/58 ms, TI 140 ms,
lice thickness of 8 mm, interslice gap of 2 mm) was
cquired in short-axis slices. Images for assessment of early
nhancement were acquired in basal, mid-papillary, and
pical short-axis slices using a T1-weighted turboFLASH
equence (TR/TE 170/1.05 ms, flip angle 12°, TI 100 ms,
lice thickness of 10 mm) before and at 40 to 70 s after
ntravenous bolus injection of 0.2 mmol/kg of gadobutrol
Gadovist, Bayer Schering, Berlin, Germany). Late gado-
inium enhancement (LGE) images were acquired 10 to 15
in after the administration of the contrast in short-axis
nd orthogonal long-axis planes using phase-sensitive
nversion-recovery sequences (TR/TE 690–850/3.2 ms,
djusted TI, slice thickness of 8 mm, interslice gap of 0.8
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CMR  cardiac magnetic
resonance
CV  coefficient of
variation
DCM  dilated
cardiomyopathy
E/E= ratio  ratio of early
mitral filling velocity to
early diastolic mitral
annular velocity
EMB  endomyocardial
biopsy
hs-cTNT  high-sensitivity
cardiac troponin T
LGE  late gadolinium
enhancement
LVEDD  left ventricular
end-diastolic dimension
LVEF  left ventricular
ejection fraction
LVRR  left ventricular
reverse remodeling
OR  odds ratio
ROC  receiver-operating
characteristicm, in-plane resolution of 1.7  1.7 mm).
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Left Ventricular Reverse Remodeling in DCM January 8, 2013:54–63Ventricular volumes, mass, and ejection fractions were
measured from cine images using Segment version 1.8 (12).
The presence and distribution of LGE were independently
determined by 2 expert radiologists (D.K. and J.W.) in a
blinded fashion. The agreement between the 2 radiologists
was as follows: kappa  0.75, 95% confidence interval: 0.53
o 0.97, p  0.001. The extent of LGE, defined by a signal
intensity 2 SDs above the mean of the remote reference
yocardium (13), was quantified semiautomatically on the
hort-axis contrast images using Matlab (Mathworks,
atick, Massachusetts) (Fig. 1). The LGE extent was
xpressed as a weight of tissue and as a percentage of LV
ass (indexed LGE extent). Quantitative assessment of
he myocardial edema ratio (T2 index) and the early
nhancement were performed as described previously
4,14). The myocardial edema ratio of 1.9 and the early
enhancement of 45% were regarded as abnormal (4,14).
The extent of LGE, the myocardial edema ratio, and the
early enhancement were analyzed by a single observer
(M.S.) blinded to the results of EMB. The corresponding
intraobserver relative variability was 5.2  4.5%, 6.9 
6.8%, and 10.1  7.3%, respectively.
Figure 1 Quantification of LGE in an Individual With LVRR at B
The figure illustrates quantification of late gadolinium enhancement (LGE) in 1 ind
12 months of follow-up (C and D). A and C show corresponding native images of
LGE. The yellow areas indicate a signal intensity 2 standard deviations above thLaboratory methods. Plasma levels of BNP were measured
immediately using a chemiluminescent immunoanalysis
(Architect BNP, Abbott Diagnostics, Abbott Park, Illi-
nois). The lower limit of detection was 10 ng/l, intra-assay
coefficient of variation (CV) 3.8%, and interassay CV
5.3%. Serum was frozen at30°C and preserved until the
hs-cTNT and galectin-3 assays. Hs-cTnT was detected
using an electrochemiluminescent immunoassay (T-hs-
STAT, Cobas e411, Roche Diagnostics, Mannheim, Ger-
many). The lower limit of detection was 5 ng/l, CV at 13
ng/l was 10%, intra-assay CV 3.2%, and interassay CV
6.2%. The upper reference limit was set at 13.5 ng/l.
Galectin-3 was measured using an enzyme-linked immu-
nosorbent assay (BioVendor, Brno, Czech Republic). The
lower limit of detection was 0.12 g/l, intra-assay CV
6.4%, interassay CV 11.4%, and expected serum levels
.62 to 6.25 g/l. Glomerular filtration rate was estimated
sing the Modification of Diet in Renal Disease formula, as
eported previously (15).
ndomyocardial biopsy and processing of samples. Be-
ore EMB, each patient underwent coronary angiography to
xclude coronary artery disease. EMB was performed via the
e and at 12 Months Follow-Up
with left ventricular reverse remodeling (LVRR) at baseline (A and B) and
a short-axis slice. B and D demonstrate the semiautomatic quantification of
n of the remote reference myocardium.aselin
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January 8, 2013:54–63 Left Ventricular Reverse Remodeling in DCMinternal jugular vein using a flexible bioptome (diameter
7-F, Cordis Corporation, Bridgewater, New Jersey) under
fluoroscopic guidance. Eight to 10 samples were obtained
from the right ventricular side of the interventricular sep-
tum. There were no complications related to the EMB
procedure. The processing and analysis of EMB specimens
were described previously (16). In brief, histopathological
diagnosis of myocarditis followed the Dallas criteria (17).
Immunohistochemical criteria of myocardial inflammation
were based on detection of mononuclear infiltrates consist-
ing of 7 CD3-positive T lymphocytes/mm2 or 14
D3-positive T lymphocytes or CD68-positive macro-
hages per 1 mm2 (18). The extent of fibrosis was assessed
visually using an ocular reticule. Quantitative polymerase
chain reactions were performed to detect human cytomeg-
alovirus, Epstein-Barr virus, human herpesvirus 6, parvovi-
rus B19, adenoviruses, and enteroviruses (comprising cox-
sackieviruses and echoviruses) in EMB samples as described
previously (16).
Statistical analysis. Categorical data were expressed as
ercentages and compared using a chi-square test or Fisher
xact test. Normally distributed continuous variables were
xpressed as the mean and standard deviation. Abnormally
istributed continuous variables were given as median and
nterquartile range. Continuous variables were compared
sing the Student t test or by the nonparametric Mann-
hitney U test, where appropriate. Variables that signifi-
antly differed between groups with and without LVRR
ere entered in a stepwise logistic regression analysis to
dentify independent predictors of LVRR at baseline, 3
onths, and 6 months of follow-up. To address the risk of
verfitting in multivariate logistic regression models, uni-
ariate logistic regression was performed for all variables
ncluded in these models (Table 1), and new multivariate
odels were created using 2 predictors of LVRR with the
est F statistic at baseline and at 3 and 6 months of
ollow-up. This approach identified the same variables and
esulted in the same models as stepwise logistic regression,
hich confirmed the reliability of the aforementioned mod-
ls. Receiver-operating characteristics (ROC) analysis was
erformed to assess the performance of selected variables to
redict LVRR. Areas under the ROC curve were calculated
lso for combinations of independent predictors of LVRR
sing logistic regression. For all tests, a probability value of
 0.05 was considered significant. All analyzes were
erformed using the statistical software SPSS (Chicago,
llinois) version 17.0.
esults
total of 44 Caucasians with recent-onset DCM participated
n the study. Their characteristics are shown in Table 2.
yocardial inflammation was found in 15 cases (34%) when
ssessed by immunohistochemical analysis. The Dallas cri-
eria were fulfilled only in 3 cases presenting with borderline myocarditis (7%). Genomes of cardiotropic viruses were
etected in 29 individuals (66%) (Table 2).
ollow-up data. A total of 39 patients (89%) completed
he 12-month follow-up, whereas 4 individuals (9%) re-
uired implantation of a ventricular assist device during the
rst 3 months, and another patient (2%) underwent urgent
eart transplantation at 4 months. In addition, 6 patients
14%) received a single-chamber implantable cardioverter-
efibrillator within the primary preventive indication. At
2 months, LVRR was observed in 20 individuals (45%).
owever, only 3 patients (7%) reached a LVEF higher
han 50%.
rediction of LVRR from baseline data. Nine of 70
aseline variables showed some predictive value for the
ubsequent LVRR (Table 2) in the univariate analysis.
ompared with the remaining individuals, LVRR was
eralded by lower serum levels of hs-cTNT, higher plasma
evels of sodium, and surprisingly, by a worse renal function.
ther predictive parameters included a higher prevalence of
yocardial inflammation in biopsy and 2 CMR variables,
amely a smaller extent of LGE and a higher myocardial
dema ratio derived from T2 imaging. Neither the presence
f viral genomes nor the extent of fibrosis in EMB samples
as related to LVRR. A multivariate analysis identified 2
ndependent predictors of LVRR at baseline: a lower value
f the indexed LGE extent and a higher value of the
Results of Multivariate AnalysisShowing the S rongest Predictors of LVRRat Baseline and 3 and 6 Months of Follow-Up
Table 1
Results of Multivariate Analysis
Showing the Strongest Predictors of LVRR
at Baseline and 3 and 6 Months of Follow-Up
Independent Predictors
of LVRR
Odds Ratio
(95% CI) p Value
Baseline
(Model 1)
1. Indexed LGE extent
2. Myocardial edema
ratio (per 0.1 unit)
0.67 (0.50–0.90) 0.008*
1.45 (1.04–2.02) 0.027*
3 Months
(Model 2)
Logarithm of BNP
(3 months)
0.14 (0.02–0.94) 0.042*
6 Months
(Model 3)
1. LVEDD index
(6 months)
0.73 (0.56–0.96) 0.014*
2. E/E= ratio (6 months) 0.56 (0.33–0.94) 0.019*
Both stepwise logistic regression of listed variables and multivariate logistic regression of 2
predictors of LVRR with the best F statistic at univariate logistic regression resulted in the same
models. Univariate F statistic is given in brackets for all variables listed, according to their
predictive power. Variables entered into the multivariate analysis: Model 1 (baseline data):
indexed LGE extent (F  6.85, p  0.012), myocardial edema ratio (F  4.27, p  0.045),
ecompensated heart failure at admission (F  4.19, p  0.047), sodium plasma level (F 
.03, p  0.051), myocarditis in biopsy (F  3.76, p  0.059), estimated glomerular filtration
ate (F 3.72, p 0.061), and high-sensitivity cardiac troponin T (F 3.10, p 0.085). Model
(3-month data): logarithm of BNP (F  6.96, p  0.012), peak exercise systolic blood
ressure (F  6.91, p  0.012), LVEDD index (6.79, p  0.013), VE/VCO2 slope (F  6.27, p 
.017), New York Heart Association (NYHA) functional class (F  5.84, p  0.021), left atrial
volume index (F  5.41, p  0.026), peak oxygen consumption (F  5.08, p  0.030), heart
rate (F  4.85, p  0.034), moderate and severe mitral regurgitation (F  4.83, p  0.034),
and restrictive mitral pattern (F  4.21, p  0.040). Model 3 (6-month data): E/Em (F  9.72,
p  0.004), LVEDD index (F  8.62, p  0.006), logarithm of BNP (F  7.83, p  0.008), left
atrial volume index (F  7.42, p  0.010), NYHA functional class (F  7.01, p  0.012), LVEF
(F  6.63, p  0.014), peak exercise systolic blood pressure (F  6.31, p  0.017), moderate
and severe mitral regurgitation (F  5.16, p  0.029), peak oxygen consumption (F  4.50,
p  0.041), and VE/VCO2 slope (F  4.11, p  0.050).
BNP B-type natriuretic peptide; CI confidence interval; E/E= ratio ratio of early mitral filling
velocity to early diastolic mitral annular velocity; LGE  late gadolinium enhancement; LVEDD 
left ventricular end-diastolic dimension; LVRR  left ventricular reverse remodeling; VE/VCO2 
elationship between minute ventilation and carbon dioxide production.yocardial edema ratio (Table 1). A simultaneous positivity
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Left Ventricular Reverse Remodeling in DCM January 8, 2013:54–63Baseline Characteristics of the Entire Study GroupTable 2 Baseline Characteristics of the Entire Study Group
Baseline
Characteristics
(n  44)
Baseline Data
LVRR Absent
(n  24)
Baseline Data
LVRR Present
(n  20)
12-Month Data
LVRR Absent
(n  19)
12-Month Data
LVRR Present
(n  20)
Age, yrs 43 11 42 14 45 8 — —
Males, % 31 (71) 16 (66) 15 (75) — —
Family history of cardiomyopathy, % 11 (25) 8 (33) 3 (15) — —
Diabetes, % 2 (4) 1 (2) 1 (2) — —
Hypertension, % 3 (7) 1 (4) 2 (10) — —
Viral prodroms, % 12 (27) 6 (25) 6 (30) — —
Duration of HF, months 2.0 (1.0–3.4) 1.6 (1.0–4.0) 2.0 (1.0–3.0) — —
HF hospitalization in previous 6 months, % 29 (66) 14 (58) 15 (75) — —
HF at admission, % 14 (32) 11 (46) 3 (15)* — —
Clinical variables
NYHA functional class, %
I 1 (2) 1 (4) 0 2 (11) 14 (70)‡
II 23 (52) 9 (37) 14 (70) 12 (63) 6 (30)
III 14 (32) 10 (42) 4 (20) 5 (26) 0
IV 6 (14) 4 (17) 2(10) 0 0
ACEI, % 40 (91) 21 (87) 19 (95) 16 (84) 19 (95)
ARB, % 4 (9%) 3 (12) 1 (5) 3 (16) 1 (5)
ACEI/ARB, 50% of recommended
dose, %
10 (23) 5 (21) 5 (25) 10 (53) 12 (60)
Beta-blockers, % 41 (93) 21 (87) 20 (100) 20 (100) 19 (100)
Beta-blockers 50% of recommended
dose, %
11 (25) 6 (25) 5 (25) 18 (95) 16 (80)
Spironolactone, % 35 (80) 21 (87) 14 (70) 14 (74) 9 (45)
Furosemide, % 40 (91) 22 (92) 18 (90) 15 (79) 13 (65)
Intravenous diuretics, % 13 (29) 10 (42) 3 (15) 0 0
Inotropes, % 6 (14) 5 (21) 1 (5) 0 0
BMI, kg/m2 25 4 25 4 25 3 27 5 26 4
Systolic BP, mm Hg 112 17 111 14 114 20 112 12 114 17
Diastolic BP, mm Hg 69 7 68 8 70 7 73 9 77 8
Heart rate, beats/min 84 19 85 19 83 19 73 13 67 9
Sinus rhythm, % 43 (98) 24 (100) 19 (95) 19 (100) 20 (100)
QRS duration, ms 106 21 108 22 102 21 114 24 99 16*
Complete LBBB, % 5 (11) 3 (12) 2 (10) 3 (16) 1 (5)
Echocardiography
LVEDD, mm 69 6 69 6 69 7 67 7 58 5‡
LVEDD, mm/m 39 3 40 3 38 3 39 4 33 2‡
Interventricular septum, mm 9 1 9 1 9 2 9 1 9 1
Posterior wall, mm 8 1 8 2 8 1 9 1 9 1
LVEF, % 23 7 24 8 22 6 26 6 42 6‡
Restrictive mitral pattern, % 17 (39) 11 (46) 6 (30) 2 (11) 0
E/E= ratio 13.2 5.3 13.7 5.5 12.5 5.2 12.0 3.6 8.2 2.8†
Left atrium short axis, mm/m 26 4 27 3 26 4 25 3 21 3†
LAVI, ml/m2 49 19 54 21 43 16 43 16 30 7†
Mitral regurgitation moderate, % 25 (57) 16 (67) 9 (42) 10 (53) 0‡
RVEDD, mm 29 6 29 6 29 6 25 4 26 3
Tricuspidal annulus Sm 9.0 2.7 8.7 3.2 9.3 2.1 11.2 2.2 10.9 1.8
Cardiopulmonary exercise testing
Exercise testing available, % 41 (93) 21 (87) 20 (100) 19 (100) 20 (100)
Duration of exercise, min 10.5 4.0 9.3 4.5 11.8 3.0 10.0 4.2 14.0 5.4*
Peak exercise heart rate, beats/min 142 17 138 19 146 13 132 22 135 18
Peak exercise systolic BP, mm Hg 135 22 130 24 140 18 138 24 155 18*
Peak oxygen consumption, ml/kg.min 19.4 4.9 18.2 6.2 20.6 2.8 19.3 6.8 23.1 5.2*
Peak oxygen consumption, % 57 16 54 20 60 8 58 20 69 16*
VE/VCO2 slope 28.8 9.2 31.0 10.9 26.4 6.6 29.4 7.7 24.4 3.7†Continued on the next page
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January 8, 2013:54–63 Left Ventricular Reverse Remodeling in DCMof both variables predicted LVRR with a sensitivity of 70%
and a specificity of 78% (Table 3). The higher prevalence of
myocarditis (50% vs. 21%, p  0.05) and elevated values of
he myocardial edema ratio on CMR in individuals with
VRR suggest that resolving myocarditis may contribute to
he process of LVRR.
ContinuedTable 2 Continued
Baseline
Characteristics
(n  44)
Laboratory examination
Sodium, mmol/l 141 2 1
Creatinine, mol/l 95 4
Estimated GFR, ml/min 79 23
BNP, ng/l 635 (276–1,081) 7
Hs-cTNT, ng/l 14.5 (5.0–30.0) 1
Galectin-3, g/l 3.0 (0.2–4.6)
Cardiac magnetic resonance imaging
CMRI available, % 44 (100)
LVEDV, ml/m2 140 40 1
LVEF, % 21 10
LV mass, g/m2 105 26 1
RVEDV, ml/m2 77 30
RVEF, % 24 8
LGE present, % 30 (68)
Central septal stripe, % 26 (59)
LGE extent, g 7.5 (0–11.6)
Indexed LGE extent, % 3.4 (0–5.0)
Myocardial edema ratio 1.5 0.3
Myocardial edema ratio 1.9 4 (9)
Early enhancement, % 21 (11.3–39.4) 2
Results of endomyocardial biopsy
Inflammation in EMB, % 15 (34)
Virus-positive EMB, % 29 (66)
Parvovirus B19-positive EMB, % 27 (61)
Parvovirus B19 500 copies/g in EMB, % 12 (27)
Parvovirus B19 in EMB, copies/g/DNA 120 (0–622) 1
Other viruses in EMB, % 5 (11)
Extent of fibrosis in EMB, % 14.5 7.6 1
Values are mean SD or n (%). Data of individuals with left ventricular reverse remodeling were com
f follow-up, p values for comparison between individuals with and without LVRR are *p  0.05,
ACEI  angiotensin converting enzyme inhibitors; ARB  angiotensin receptor blockers; BM
ndomyocardial biopsy; GFR  glomerular filtration rate; HF heart failure; hs-cTNT  high-sen
entricular; LVEDV  left ventricular end-diastolic volume; LVEF  ejection fraction; RVEDD  r
entricular ejection fraction; Sm  systolic; other abbreviations as in Table 1.
Results of ROC Analysis With Selected Cutoff Points of Variables PTable 3 Results of ROC Analysis With Selected Cutoff Points o
Variable AUC (95%
Baseline Indexed LGE extent, % 0.73 (0.58–
Myocardial edema ratio 0.67 (0.51–
Indexed LGE extent and myocardial edema ratio
3 Months BNP, ng/l 0.79 (0.64–
6 Months LVEDD, mm/m 0.83 (0.70–
E/E= ratio 0.82 (0.69–
BNP, ng/l 0.81 (0.67–
LVEDD and E/E= ratioAUC  area under the curve; ROC  receiver-operating characteristic; other abbreviations as in Table 1.rediction of LVRR from the follow-up data. Fifteen of
0 follow-up variables predicted LVRR in the univariate
nalysis. These predictors included a better exercise capac-
ty, a lower LVEDD, a higher LVEF, less severe mitral
egurgitation, a smaller left atrial volume, and lower values
f noninvasive indicators of the LV filling pressure (E/E=
ne Data
Absent
24)
Baseline Data
LVRR Present
(n  20)
12-Month Data
LVRR Absent
(n  19)
12-Month Data
LVRR Present
(n  20)
2 142 2* 140 2 141 3
19 104 27* 80 16 92 27
25 71 18* 92 25 84 27
6–1,264) 375 (229–933) 172 (56–377) 25 (13–55)†
0–76.7) 9.5 (3.2–18.5)* — —
4–5.1) 1.5 (0.2–4.5) — —
0) 20 (100) 12 (63) 18 (90)
45 132 35 113 26 71 12‡
10 21 10 28 5 42 5‡
26 105 28 86 14 80 18
33 75 27 66 22 60 13
9 24 8 35 8 45 7†
) 12 (60) 7 (58) 8 (44)
) 11 (55) 5 (28) 4 (33)
4–16.4) 2.9 (0–8.4)* 4.6 (0–10.3) 0 (0–4.1)
1–7.8) 1.4 (0–4.3)† 2.2 (0–7.3) 0 (0–2.5)
0.2 1.6 0.4* 1.2 0.3 1.3 0.2
0 4 (20)* 0 0
.9–42) 15.6 (6.6–36.9) — —
) 10 (50)* — —
) 12 (60) — —
) 10 (50) — —
) 6 (33) — —
547) 72 (0–922) — —
4 (20) — —
8.2 13.5 6.9 — —
with the remaining individuals at baseline and 12months of follow-up. At baseline and 12months
.01, and ‡p  0.001.
dy mass index; BP  blood pressure; CMRI  cardiac magnetic resonance imaging; EMB 
cardiac troponin T; LAVI  left atrial volume index; LBBB  left bundle branch block; LV  left
tricular end-diastolic dimension; RVEDV  right ventricular end-diastolic volume; RVEF  right
ting LVRRiables Predicting LVRR
p Value Cutoff Point Sensitivity (%) Specificity (%)
0.009 5 90 46
0.043 1.30 80 44
5 and 1.30 70 78
0.002 344 95 50
0.000 38 85 68
0.001 11.7 100 53
0.001 168 95 63
38 and 11.7 85 84Baseli
LVRR
(n 
40
88
86
87 (37
7.5 (7.
3.6 (0.
24 (10
47
22
06
80
23
18 (75
15 (62
9.4 (2.
4.3 (1.
1.4
5.5 (17
5 (21
17 (71
17 (71
6 (24
20 (0–
1 (4)
5.4
pared
†p  0
I  bo
sitivityredicf Var
CI)
0.88)
0.84)
0.94)
0.96)
0.96)
0.95)
ween in
bbrevia
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level) (Table 4, Fig. 2). Importantly, there were no differ-
ences in the use of heart failure medication in both groups.
At 3 months, the latest plasma level of BNP was the most
powerful predictor of LVRR (Table 1). Specifically, BNP
level 344 ng/l predicted LVRR with a sensitivity of
Comparison of Individuals With and Without LVRR at 3 and 6 MontTable 4 Comparison of Individuals With and Without LVRR at 3
3-Month FU Data
LVRR Absent
(n  20)
NYHA functional class, %
I 2 (10)
II 11 (55)
III 17 (35)
IV 0
ACEi, % 17 (85)
ARB, % 3 (15)
ACEi/ARB, 50% of recommended dose, % 7 (35)
Beta-blockers, % 20 (100)
Beta-blockers 50% of recommended dose, % 10 (50)
Spironolactone, % 15 (75)
Furosemide % 16 (80)
Furosemide 40 mg/day, % 12 (60)
BMI, kg/m2 26 5
Systolic BP, mm Hg 110 14
Diastolic BP, mm Hg 71 9
Heart rate, beats/min 82 14
Sinus rhythm, % 20 (100)
QRS duration, ms 110 24
Complete LBBB, % 3 (15)
LVEDD, mm 69 8
LVEDD, mm/m 40 4
Interventricular septum, mm 9 1
Posterior wall, mm 9 1
LVEF, % 26 7
Restrictive Mi pattern, % 8 (40)
E/E= ratio 13.4 7.4
Left atrium short axis, mm/m 25 3
Left atrium long axis, mm/m 33 4
LAVI, ml/m2 46 17
Mitral regurgitation moderate, % 10 (50)
RVEDD, mm 27 4
Tricuspidal annulus Sm 10.0 2.6
TAPSE, mm 19 4
Exercise testing available, % 20 (100)
Duration of exercise, min 8.4 3.9
Peak exercise heart rate, beats/min 133 19
Peak exercise systolic BP, mm Hg 129 21
Peak oxygen consumption, ml/kg/min 17.9 5.5
Peak oxygen consumption, % 53 19
VE/VCO2 slope 30.1 8.7
Sodium, mmol/l 141 2
Creatinine, mol/l 85 27
Estimated GFR, ml/min 91 29
B-type natriuretic peptide, ng/l 350 (149–731)
Values are n (%) or mean  SD. At 3 and 6 months of follow-up, the p values for comparison bet
FU  follow-up; Mi  mitral inflow; TAPSE  tricuspid annular systolic plane excursion; other a95% and a specificity of 50% (Table 3). The conventionalmethods (LVEDD index and E/E= ratio) became the
strongest predictors of LVRR as late as after 6 months of
follow-up. Table 5 illustrates improvement in areas under
the ROC curve for combinations of follow-up variables
and even for combinations of baseline CMR variables
with the follow-up data. Surprisingly, both the baseline
FU6 Months of FU
3-Month FU Data
LVRR Present
(n  20)
6-Month FU Data
LVRR Absent
(n  19)
6-Month FU Data
LVRR Present
(n  20)
6 (30)† 3 (16) 9 (45)†
14 (70) 9 (47) 11 (55)
0 7 (37) 0
0 0 0
19 (95) 16 (84) 19 (95)
1 (5) 3 (16) 1 (5)
7 (35) 6 (32) 9 (45)
20 (100) 20 (100) 19 (100)
9 (45) 14 (74) 13 (65)
15 (75) 14 (74) 10 (50)
18 (90) 15 (79) 16 (80)
15 (75) 12 (63) 11 (55)
26 3 27 4 26 4
112 11 114 10 112 12
70 8 73 7 73 8
72 11* 74 15 70 12
19 (95) 19 (100) 20 (100)
99 17 110 20 99 16
1 (5) 3 (16) 1 (5)
64 8 67 9 61 6†
36 4† 39 4 34 3‡
9 2 9 1 8 1
9 1 9 1 8 1
30 7 28 7 37 10†
0† 2 (10) 0
8.8 3.3* 12.2 3.7 8.0 1.8†
22 3† 26 4 21 3‡
28 3‡ 31 4 27 3†
34 10* 45 17 30 8†
3 (15)* 8 (42) 1 (5)†
27 3 27 3 27 3
10.7 2.1 10.3 2.0 11.4 2.4
21 5 21 4 20 4
20 (100) 19 (100) 20 (100)
13.5 8.4† 9.0 4.0 13.4 4.5†
145 18 133 22 136 19
150 19† 133 19 152 20†
22.2 4.5† 18.0 5.3 21.9 3.2†
65 14† 54 17 67 14†
23.5 3.2† 29.5 8.8 24.5 4.0†
140 2 140 2 140 2
91 26 79 16 94 25*
84 24 94 28 81 25
101 (70–196)† 244 (66–538) 53 (36–70)‡
dividuals with and without LVRR are *p  0.05, †p  0.01, and ‡p  0.001.
tions as in Tables 1 and 2.hs ofandindexed LGE extent and the myocardial edema ratio
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levels at 3 months and the echocardiographic variables at
6 months (Table 5).
CMR findings at 12 months of follow-up. A follow-up
CMR was available in 30 individuals. At baseline, LGE was
present in 20 (67%) of 30 subjects with the follow-up CMR.
At 12 months, LGE persisted in 13 individuals (43%) and
disappeared in 7 individuals (23%). Of 10 subjects who were
LGE negative at baseline, 8 individuals remained LGE
negative (27%), and 2 individuals (7%) developed a new
Figure 2 Longitudinal Changes in Median BNP levels and LVED
The light blue columns illustrate significantly lower plasma levels of B-type natriur
pared with the remaining individuals (dark blue columns) at 3, 6, and 12 months
AUC Calculated for Combinations of Independent Predictors of LVRTable 5 AUC Calculated for Combinations of Independent Pred
Vari
Baseline iLGE
ER
iLGE and ER
3 Months BNP (3 months)
6 Months iLVEDD (6 months)
E/E= ratio (6 months)
iLVEDD (6 months) and E/E= ratio (6 mo
3 Months  baseline BNP (3 months) and iLGE
BNP (3 months) and ER
BNP (3 months) and iLGE and ER
6 Months  3 months iLVEDD (6 months) and E/E= ratio (6 mo
6 Months 3 months  baseline iLVEDD (6 months) and E/E= ratio (6 mo
iLVEDD (6 months) and E/E= ratio (6 moWe observed an increase in the predictive performance in these combinations.
ER  myocardial edema ratio; iLGE  indexed extent of late gadolinium enhancement; iLVEDD  indeLGE lesion. There were no statistically significant dif-
ferences in the baseline and follow-up distribution of
LGE in the entire group or within subgroups defined
according to LVRR (data not shown). Importantly, both
the LGE extent (5.5 [0 to 11.6] g vs. 1.3 [0 to 6.0] g, p 
.001) and the myocardial edema ratio (1.53  0.37 vs.
1.29  0.25, p  0.002) decreased during follow-up.
Although the baseline values of the LGE extent and the
myocardial edema ratio were significantly different be-
tween the aforementioned groups (Table 2), the absolute
ex in Individuals With and Without LVRR
ptide (BNP) in the group with left ventricular reverse remodeling (LVRR) com-
ow-up. LVEDD  left ventricular end-diastolic dimension.
ing Logistic Regressionof LVRR Using Logistic Regression
) AUC (95% CI) p Value
0.73 (0.58–0.88) 0.009
0.67 (0.51–0.84) 0.043
0.85 (0.72–0.96) 0.001
0.79 (0.64–0.94) 0.002
0.83 (0.70–0.96) 0.000
0.82 (0.69–0.96) 0.001
0.90 (0.80–1.00) 0.001
0.84 (0.71–0.97) 0.001
0.84 (0.71–0.98) 0.001
0.89 (0.78–1.00) 0.001
nd BNP (3 months) 0.91 (0.81–1.01) 0.001
nd BNP (3 months) and iLGE 0.94 (0.86–1.02) 0.001
nd BNP (3 months) and iLGE and ER 0.96 (0.89–1.03) 0.001D Ind
etic pe
of follR Usictors
able(s
nths)
nths) a
nths) a
nths) axed left ventricular end-diastolic dimension; other abbreviations as in Tables 1 and 3.
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both groups (data not shown).
Discussion
This appears to be the first report on prediction of LVRR in
subjects with recent-onset DCM directly comparing perfor-
mance of contrast-enhanced CMR, serial BNP testing, and
EMB results. The main findings can be summarized as
follows. First, the lower extent of LGE and the higher
myocardial edema ratio at CMR examination were the most
important baseline predictors of LVRR stronger than EMB
results, values of biomarkers, and conventional methods.
Second, the latest BNP plasma level was the most powerful
predictor of LVRR at 3 months of follow-up. Third, the
conventional methods, namely indexed LVEDD and the
E/E= ratio, became the strongest predictors of LVRR as
late as after 6 months of follow-up. Fourth, the predictive
performance of the follow-up variables was improved by
combination with baseline CMR data. Finally, the higher
prevalence of myocarditis and elevated values of the myo-
cardial edema ratio on CMR in individuals with LVRR
suggest that resolving myocarditis may contribute to the
process of LVRR.
Comparison with previous studies of LVRR. LVRR in
individuals with recent-onset DCM was described by Dec
et al. in 1985 (19). A larger study by Steimle et al. (20),
conducted before the era of beta-blockers, revealed an
incidence of LVRR (defined as an increase of LVEF 15%
at 12 months) of 27%. LVRR was predicted by a shorter
symptom duration and less severe hemodynamic decompen-
sation. Interestingly, EMB results, fulfilling the Dallas
criteria of myocarditis in 9%, played no role in prediction of
LVRR (20). Over time, advances in heart failure pharma-
cotherapy have increased the incidence of LVRR both in
the general heart failure population (21,22) and in patients
with recent-onset DCM (23,24). Along these lines, McNa-
mara et al. (23,24) reported data from Intervention in
Myocarditis and Acute Cardiomyopathy trials IMAC-1 and
IMAC-2, showing the incidence of LVRR (defined as an
increase of LVEF 10%) of 56% at 12 months and 70% at
6 months, respectively. The prevalence of LVRR in our
study (45%) was similar to that in the IMAC-1 study. The
epidemiological IMAC-2 trial reported the following pre-
dictors of LVRR: a lower New York Heart Association
functional class and LVEDD together with a higher systolic
blood pressure and non-black race. However, none of these
variables had sufficient power for clinical decision making.
Importantly, our study revealed novel predictors of LVRR
with an acceptable predictive capacity, namely, variables
derived from CMR and serial BNP testing. In addition, we
evaluated the predictors of LVRR, not only at baseline, but
also longitudinally. As a result, we could identify specific
cutoff points for each follow-up period and showed that the
novel predictors provided an earlier prediction of LVRR
than the conventional methods.The role of CMR in DCM patients. Most studies as-
sessed the prognostic value of CMR, specifically of LGE, in
individuals with a long-term established diagnosis of DCM
(25,26). There is only 1 CMR study that evaluated individ-
uals with recent-onset DCM and attempted to predict
improvement in LV systolic function defined as an increase
in LVEF 5% at 5 months of follow-up (27). Leong et al.
(27) demonstrated in that study an inverse correlation
between the LGE extent and improvement in LVEF.
However, their study population was different from our
cohort because individuals with suspected myocarditis hav-
ing either abnormal troponin I levels or evidence of myo-
cardial edema on T2-weighted CMR were excluded.
Tachycardia-induced cardiomyopathy, however, was not
considered to be an exclusion criterion.
In our study, we excluded individuals with suspected
tachycardia-induced cardiomyopathy and alcoholic cardio-
myopathy, which are known as highly reversible disease
entities. We found no good reason not to recruit troponin
I–positive individuals with recent-onset DCM who repre-
sented almost one-third of our consecutive patients. We
believe that our inclusion criteria, the definition of LVRR,
and the structured 1-year follow-up support the applicabil-
ity of our results in clinical practice.
Therapeutic implications. The role of CMR, specifically
the extent of LGE, to predict a response to pharmacother-
apy in chronic heart failure patients was reported by Bello et
al. (28) already in 2003. This was the first study that opened
the door to the personalized medicine in this field. We
extended the available evidence by inclusion of T2-weighted
CMR and serial BNP testing into prediction of LVRR in
the specific setting of recent-onset DCM. Improved iden-
tification of DCM patients with subsequent LVRR might
be helpful for the cost-effective use of implantable
cardioverter-defibrillators in the primary prevention of sud-
den cardiac death, and it could also be used for optimal
timing of transplantation referral in DCM patients. There-
fore, we propose to include CMR into the baseline assess-
ment of patients with recent-onset DCM and to use the
serial BNP measurement during the follow-up.
Study limitations. First, the small study group size that
reflects rather complex study design with the use of EMB
and repeated controls may limit general applicability of the
study results. Second, although the serial assessment of
hs-cTNT could have improved the prediction of LVRR
(29), this was not known at conception of the study design.
Third, because the accuracy of regression coefficients is
driven by the number of events, multivariate models includ-
ing more than 2 independent variables for prediction of 20
events may be inaccurate (30). To address the risk of
overfitting in multivariate logistic regression models, uni-
variate logistic regression was performed for all variables
included in these models, and new multivariate models were
created using 2 predictors of LVRR with the best F statistic
at baseline and at 3 and 6 months of follow-up. This
approach identified the same variables and resulted in the
23
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firmed the reliability of the aforementioned models. Last,
the study results have to be considered specific for the
present subject sample and may vary in different
populations.
Conclusions
This study showed that CMR findings, specifically the
extent of LGE and the myocardial edema ratio, together
with the serial BNP testing provide a better prediction of
LVRR in patients with recent-onset DCM than EMB
results, the use of other biomarkers, and the conventional
methods of cardiological follow-up. The higher prevalence
of myocarditis and elevated values of the myocardial edema
ratio in individuals with LVRR suggest that resolving
myocarditis may contribute to the process of LVRR.
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